PharmaResearch Completes Five-Market Roadshow for REJURAN's European Expansion

PharmaResearch Completes Five-Market Western Europe Roadshow for REJURAN

PharmaResearch Co., Ltd., a leading South Korean regenerative medicine firm, has recently wrapped up a significant roadshow across five major markets in Western Europe to promote its skin booster, REJURAN. This initiative marks the brand’s strategic expansion into the European market, showcasing the innovative PN-based technology of REJURAN, which has gained substantial traction in Asia.

The roadshow, which took place between April and May 2026, began with an impactful symposium held in the Benelux region on April 22 and 23. This event served as a vital introduction for healthcare practitioners (HCPs) from Belgium and the Netherlands, who gathered to learn more about the clinical applications and efficacy of REJURAN's unique formulation. Following this, events in the United Kingdom and Switzerland further engaged local medical professionals and industry stakeholders, reinforcing the product’s reception.

Among the highlights of the roadshow were presentations led by renowned experts and Key Opinion Leaders (KOLs) in the field. They elaborated on clinical results and treatment protocols for various applications of REJURAN, catering to different zones of the face, including the delicate eye area and specific solutions for wrinkles and scars. The comprehensive approach of the sessions sought to familiarize practitioners with REJURAN's versatility and effectiveness in aesthetic treatments.

The success of this roadshow underscores a growing interest in regenerative medicine products in Europe, despite the market still being in its early stages. Attendees expressed keen interest, asking thoughtful questions about REJURAN’s characteristics and practical applications, signaling a promising reception from the aesthetic community.

In anticipation of continued growth, PharmaResearch is planning subsequent events in Italy, Poland, and France later this year. This will establish further engagement with healthcare professionals and expand the reach of REJURAN in the international landscape. The company's Chief Customer Officer at VIVACY, Vera Tual, noted the overwhelming enthusiasm for REJURAN among attendees, particularly in light of its established reputation from the Asian market.

PharmaResearch began exporting REJURAN to Europe in January, working diligently to cultivate a local distribution network. Positive feedback from early adopters of the product has prompted plans for scaling its availability and enhancing clinical education opportunities across the continent.

A spokesperson from PharmaResearch mentioned, "Interest in PN-based injectables is on the rise, and we see this as an optimal time to present REJURAN as a dependable skin booster, supported by our proprietary DNA Optimizing Technology (DOT™)." They emphasized the favorable initial response, leading to an increase in their internal targets for product distribution and education initiatives.

PharmaResearch continues on its mission to revolutionize aesthetics with its advanced formulas, ultimately improving the quality of life through innovative regenerative medicine solutions. With REJURAN, the company aims to solidify its presence not only in Europe but on a global scale.

In summary, the successful completion of the five-market roadshow highlights PharmaResearch's commitment to broadening the horizons for REJURAN, while fostering deeper relationships with medical professionals throughout Europe. As the company gears up for the next phases of its European rollout, the future looks promising for this groundbreaking skin booster.